AnalystsRoy Buchanan
Roy Buchanan's Stock Forecasts

Analyst Ranking
Top 12%
#596 out of 5020 analysts
Average Return
+17.7%
Win Rate
49%35 out of 72
Risk vs Reward
Poor
Good

Roy Buchanan's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Abivax SaABVX
+1,169.59%$6.38$81.00
2025-01-09 -
2025-09-17
Buy
Cidara Therapeutics IncCDTX
+248.09%$18.63$64.85
2025-05-08 -
2025-09-17
Buy
Cidara Therapeutics IncCDTX
+207.05%$21.12$64.85
2025-04-28 -
2025-09-17
Buy
Cidara Therapeutics IncCDTX
+186.12%$22.67$64.85
2025-06-01 -
2025-09-17
Buy
Cidara Therapeutics IncCDTX
+181.96%$23.00$64.85
2025-03-11 -
2025-09-17
Buy

Roy Buchanan Analyst Color

Get additional color on Roy Buchanan's coverage of popular stocks

Roy Buchanan's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Dynavax Technologies CorpDVAX
8Buy$32.00+234.38%Reiterates
a month ago
Enanta Pharmaceuticals IncENTA
14Buy$25.00+231.56%Maintains
a month ago
Cidara Therapeutics IncCDTX
7Buy$66.00+1.77%Maintains
a month ago
Polypid LtdPYPD
2Buy$14.00+315.43%Maintains
3 months ago
Curevac NvCVAC
9Buy$10.00+86.57%Reiterates
4 months ago
An2 Therapeutics IncANTX
8Buy$2.00+55.04%Maintains
4 months ago
Inovio Pharmaceuticals IncINO
3Buy$18.00+725.69%Reiterates
6 months ago
Esperion Therapeutics IncESPR
3Buy$4.00+47.06%Reiterates
7 months ago
Ironwood Pharmaceuticals IncIRWD
1Buy$14.00+993.75%Maintains
8 months ago
Abivax SaABVX
1Buy$33.00-59.26%Reiterates
8 months ago
Hookipa Pharma IncHOOK
2Buy$7.00+694.55%Maintains
10 months ago
Gritstone Bio IncGRTSQ
4Buy$5.00N/AReiterates
a year ago
Arbutus Biopharma CorpABUS
5Buy$5.00N/AMaintains
a year ago
Pardes Biosciences IncPRDS
2Buy$5.00N/AMaintains
3 years ago
Argenx SeARGX
2Buy$448.00N/AMaintains
3 years ago
Cormedix IncCRMD
1Hold$16.00N/AMaintains
3 years ago
Ibio IncIBIO
1Buy$750.00N/AInitiates Coverage On
4 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.